<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>MRC Centre for Inflammation Research</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/25A0293A-A559-4D4B-BF20-53059372763D"><gtr:id>25A0293A-A559-4D4B-BF20-53059372763D</gtr:id><gtr:firstName>Karen</gtr:firstName><gtr:surname>Mackenzie</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701350"><gtr:id>E7E7749A-FB98-4715-97B2-A3AEA4086E76</gtr:id><gtr:title>The influence of viral infection on therapeutic immune tolerance in allergic airways disease.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0701350</gtr:grantReference><gtr:abstractText>Allergic airways disease such as asthma is rising in children. Allergy can be triggered by different environmental allergens (e.g. pollen). In susceptible children, inhaling allergens may cause allergic reactions with breathing problems, sometimes requiring hospital treatment. Treatment with small allergen fragments, called peptide-based immunotherapy (PIT), can render allergic patients tolerant, i.e. unresponsive to their allergen, without the risk of allergic reactions. How tolerance to allergen develops is not fully understood. 
Children commonly suffer from viral infections such as the common cold and can sometimes develop allergic airways disease thereafter. Why this happens is unclear, but it is thought that viral infections interfere with the immune cells that maintain tolerance. Thus, there is concern that PIT may be ineffective or even detrimental if it coincides with a viral infection. Using a mouse model, I will study how immune cells contribute to the development of tolerance following PIT. I will then determine the effects of viral infection both on these cells and on the ability of PIT to induce tolerance. Understanding these interactions is vital if PIT is to be used safely in treating children with allergy. In addition, my studies will further our understanding of the mechanisms underlying virus induced allergy.</gtr:abstractText><gtr:technicalSummary>Aims and objectives: 
Respiratory allergy including asthma is an increasing problem in children. Immunotherapy with allergen protein is used to induce tolerance but poses the risk of severe allergic reactions including anaphylaxis due to IgE binding. Peptide-based immunotherapy (PIT) may convey T cell tolerance without providing IgE binding epitopes, thus negating the risk of anaphylaxis. The exact mechanisms of PIT and the impact of concomitant viral infections on tolerance induction are not known. 
This project will investigate how tolerance induced by PIT is influenced by concomitant viral infection. Extending an existing ovalbumin (OVA)-specific, transgenic, CD4+ T cell receptor mouse (OT-II) model of PIT into an allergic airways disease setting, we will assess the contribution of foxp3+ regulatory T cells (Treg) to the development of tolerance. Whether tolerance can be induced and maintained during an ongoing respiratory viral infection will be determined. 

Design: We will utilise a murine model of allergic airways disease induced by intraperitoneal sensitization to OVA/alum followed by intratracheal OVA challenges. Tolerance will be induced using intravenous OVA-peptide either prophylactically (before sensitisation) or therapeutically (after sensitization). Respiratory syncytial virus (RSV) infection prior to or following PIT will reveal the impact of infection on development and maintenance of allergen tolerance. 

Methods: Airway inflammation and immune activation will be demonstrated by lung histology, T cell activation studies and assessment of OVA-specific antibody levels. Transfer of OT-II T cells will enable precise analysis of dendritic cell and T cell functions and phenotype during sensitisation, PIT and RSV-infection, allowing analysis of co-stimulatory molecules and cytokine production. Foxp3-reporter mice will enable assessment of expansion or conversion of Tregs in these studies. 

Scientific and medical opportunities: PIT is an attractive treatment approach for allergic diseases. Limited human trials have produced promising, yet unpredictable results in part due to incomplete understanding of the immune mechanisms behind PIT. This project offers important scientific opportunities for further clarification of the mechanisms leading to immune tolerance in PIT. 

Viral infections are known to enable sensitization to non-immunogenic antigens and are thought to facilitate the development of allergic childhood asthma. Thus, it seems possible that PIT in children may be ineffective or even detrimental if complicated by viral infection. This study will help clarify the influence of viral infection on PIT. Such knowledge is required if PIT is to be used safely in children in the future.</gtr:technicalSummary><gtr:fund><gtr:end>2011-04-20</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-04-21</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>243926</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Inflammation Research</gtr:department><gtr:description>in vivo effects of lactoferrin</gtr:description><gtr:id>94025C8B-7A3D-4BA5-9DFD-4C48E79CEF4E</gtr:id><gtr:impact>Collaboration and publication, ID 19918259</gtr:impact><gtr:outcomeId>EF25659ACC4-1</gtr:outcomeId><gtr:partnerContribution>I have learnt about the role of lactoferrin in eosinophil migration which is relevant to my ongoing research.</gtr:partnerContribution><gtr:piContribution>Helping to apply lactoferrin to in vivo allergy models</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Max Perutz Science Writing Prize</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>98326F84-608D-4B52-9EE6-897C7E423895</gtr:id><gtr:impact>Writing an article aimed at the public about my ongoing PhD project. This will be published in an MRC booklet.

Having the opportunity to attend a writing workshop has given me skills I can utilise in my future science writing.</gtr:impact><gtr:outcomeId>A079C5EAE1E</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>800</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>British Society for Immunology ICI Travel Award</gtr:description><gtr:end>2010-08-02</gtr:end><gtr:fundingOrg>British Society For Immunology</gtr:fundingOrg><gtr:id>6D01A216-BE84-47F3-94FA-E0754ED926D2</gtr:id><gtr:outcomeId>qXDw5mNV1sw0</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2010-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>7100</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The Dowager Countess Eleanor Peel Trust small grant</gtr:description><gtr:end>2012-11-02</gtr:end><gtr:fundingOrg>The Dowager Countess Eleanor Peel Trust</gtr:fundingOrg><gtr:id>8E37999C-BAE5-4C2A-B25B-A8739F41F2C1</gtr:id><gtr:outcomeId>FwELNTwprqy</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>49924</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Testing the limits of peptide immunotherapy - how do effector and memory T cells respond?</gtr:description><gtr:end>2012-11-02</gtr:end><gtr:fundingOrg>Asthma UK</gtr:fundingOrg><gtr:id>45C10F5B-20AA-48EF-8FE8-3FFB374893C2</gtr:id><gtr:outcomeId>i8BbZwo3NMH0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>9584</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Tenovus Scotland small grant</gtr:description><gtr:end>2012-11-02</gtr:end><gtr:fundingOrg>Tenovus Scotland</gtr:fundingOrg><gtr:id>0E6CA743-8F8B-4272-8A1D-84B97977445E</gtr:id><gtr:outcomeId>jP835d8MUKL</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7BC72532-FA6B-421A-B695-BC0941F8088E</gtr:id><gtr:title>Cathelicidin host defence peptide augments clearance of pulmonary Pseudomonas aeruginosa infection by its influence on neutrophil function in vivo.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/903db3e2d28bdd3cef30d4206a136bab"><gtr:id>903db3e2d28bdd3cef30d4206a136bab</gtr:id><gtr:otherNames>Beaumont PE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_540e158e158145216</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D39368C-AF81-41F9-85E2-3031CA386B12</gtr:id><gtr:title>Inhibition of eosinophil migration by lactoferrin.</gtr:title><gtr:parentPublicationTitle>Immunology and cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/006889a291abd81487dad432f5c839e0"><gtr:id>006889a291abd81487dad432f5c839e0</gtr:id><gtr:otherNames>Bournazou I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0818-9641</gtr:issn><gtr:outcomeId>9DF17796E08</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E78FB3CE-B894-42D2-AD62-8BFF73A4CEA5</gtr:id><gtr:title>Combination peptide immunotherapy based on T-cell epitope mapping reduces allergen-specific IgE and eosinophilia in allergic airway inflammation.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdb7873ab95bbdbd121d17277f61d31e"><gtr:id>cdb7873ab95bbdbd121d17277f61d31e</gtr:id><gtr:otherNames>Mackenzie KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>pm_16265_25_23113712</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>197A7FF4-1EAE-407C-BFC1-C5EEFA2506E4</gtr:id><gtr:title>Peptide immunotherapy for childhood allergy - addressing translational challenges.</gtr:title><gtr:parentPublicationTitle>Clinical and translational allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdb7873ab95bbdbd121d17277f61d31e"><gtr:id>cdb7873ab95bbdbd121d17277f61d31e</gtr:id><gtr:otherNames>Mackenzie KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2045-7022</gtr:issn><gtr:outcomeId>CbrnZ83xVbQ</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701350</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>